ISRG analyst scorecard · Intuitive Surgical
64 rating actions on ISRG in the last 12 months. Of 72 price targets that resolved, 8 were reached while they stood, 62 were replaced by the same firm first, and 2 fell short at their deadline. Ratings: 78% Buy-type, 22% Hold-type, 0% Sell-type. Consensus target $483, 8% above the last close.
Checked through 2026-10-29 · last close $448.36 (2026-10-29). Rebuilt every morning.
Targets reached while they stood
11.1% 8 of 72
Replaced before the deadline
86.1%
Short at the deadline
2.8%
Ratings vs XLV
1 of 15
Buy / Hold / Sell, 12 mo
78 / 22 / 0%
Consensus target
$483 +7.6%
What the Holds say: 14 Hold-type ratings on ISRG in the last 12 months carried a median target +13% from the price on the day; 21% sat below it.
The 4 upgrades on ISRG came after an average -4.8% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| BTIG | Buy | 2026-10-21 | $454 | 1 | 8 | 9 | 0 of 1 |
| Citigroup | Buy | 2026-07-17 | $500 | 0 | 6 | 6 | 0 of 1 |
| JPMorgan | Overweight | 2026-10-21 | $475 | 0 | 1 | 2 | 0 of 1 |
| Wells Fargo | Overweight | 2026-10-21 | $486 | 0 | 5 | 5 | 0 of 1 |
| Raymond James | Outperform | 2026-07-17 | $483 | 0 | 2 | 2 | 0 of 1 |
| Stifel | Buy | 2026-07-17 | $550 | 1 | 0 | 1 | 0 of 1 |
| Mizuho | Neutral | 2026-10-21 | $400 | 1 | 2 | 3 | — |
| Leerink Partners | Outperform | 2026-10-21 | $503 | 0 | 2 | 2 | — |
| Baird | Outperform | 2026-10-21 | $550 | 1 | 3 | 4 | 0 of 1 |
| TD Cowen | Buy | 2026-10-21 | $485 | 0 | 2 | 2 | — |
| RBC Capital | Outperform | 2026-10-21 | $550 | 0 | 7 | 7 | 0 of 1 |
| Piper Sandler | Overweight | 2026-07-17 | $470 | 0 | 6 | 6 | 0 of 1 |
| Bernstein | Outperform | 2026-07-17 | $685 | 0 | 2 | 2 | — |
| Evercore ISI Group | In-Line | 2026-10-21 | $385 | 2 | 0 | 2 | — |
| Barclays | Overweight | 2026-10-21 | $500 | 0 | 5 | 5 | 0 of 1 |
| Truist Securities | Buy | 2026-07-16 | $510 | 1 | 8 | 9 | 0 of 1 |
| UBS | Neutral | 2026-03-17 | $550 | 0 | 3 | 3 | — |
| Oppenheimer | Outperform | 2026-08-12 | $500 | — | — | 0 | — |
| HSBC | Hold | 2026-07-30 | $931 | — | — | 0 | — |
| BMO Capital | Outperform | 2026-07-09 | $518 | — | — | 0 | — |
| Bank of America | Buy | 2026-05-18 | $520 | — | — | 0 | — |
| Goldman Sachs | Buy | 2026-04-09 | $609 | — | — | 0 | — |
| Freedom Capital Markets | Buy | 2026-01-27 | $610 | — | — | 0 | — |
| Freedom Broker | Buy | 2026-01-26 | $610 | — | — | 0 | 0 of 1 |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor ISRG carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | Leerink Partners | Outperform | maintained | $428.12 | $503 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | JPMorgan | Overweight | maintained | $428.12 | $475 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | Evercore ISI Group | In-Line | maintained | $428.12 | $385 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | Wells Fargo | Overweight | maintained | $428.12 | $486 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | TD Cowen | Buy | reiterated | $428.12 | $485 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | Barclays | Overweight | maintained | $428.12 | $500 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | RBC Capital | Outperform | maintained | $428.12 | $550 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | Mizuho | Neutral | maintained | $428.12 | $400 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | Baird | Outperform | maintained | $428.12 | $550 | running to 2027-10-21 | +6.6% |
| 2026-10-21 | BTIG | Buy | reiterated | $428.12 | $454 | running to 2027-10-21 | +6.6% |
| 2026-10-12 | BTIG | Buy | maintained | $427.64 | $454 | running to 2027-10-12 | +15.8% |
| 2026-10-07 | Barclays | Overweight | initiated | $414.52 | $485 | replaced 2026-10-21, new $500 | +13.0% |
| 2026-09-08 | BTIG | Buy | reiterated | $350.16 | $469 | replaced 2026-10-12, new $454 | -7.6% |
| 2026-08-12 | Oppenheimer | Perform → Outperform | upgrade | $401.27 | $500 | running to 2027-08-12 | -1.4% |
| 2026-07-30 | HSBC | Buy → Hold | downgrade | $352.97 | $931 | running to 2027-07-30 | -11.2% |
| 2026-07-17 | Raymond James | Outperform | maintained | $345.42 | $483 | running to 2027-07-17 | -14.1% |
| 2026-07-17 | Piper Sandler | Overweight | reiterated | $345.42 | $470 | running to 2027-07-17 | -14.1% |
| 2026-07-17 | JPMorgan | Overweight | maintained | $345.42 | $450 | replaced 2026-10-21, new $475 | -14.1% |
| 2026-07-17 | Mizuho | Neutral | maintained | $345.42 | $400 | reached 2026-08-11 | -14.1% |
| 2026-07-17 | Wells Fargo | Overweight | maintained | $345.42 | $487 | replaced 2026-10-21, new $486 | -14.1% |
| 2026-07-17 | TD Cowen | Buy | maintained | $345.42 | $485 | running to 2027-07-17 | -14.1% |
| 2026-07-17 | Evercore ISI Group | In-Line | maintained | $345.42 | $375 | reached 2026-08-03 | -14.1% |
| 2026-07-17 | RBC Capital | Outperform | maintained | $345.42 | $575 | replaced 2026-10-21, new $550 | -14.1% |
| 2026-07-17 | Stifel | Buy | maintained | $345.42 | $550 | running to 2027-07-17 | -14.1% |
| 2026-07-17 | Citigroup | Buy | maintained | $345.42 | $500 | running to 2027-07-17 | -14.1% |
| 2026-07-17 | Bernstein | Outperform | maintained | $345.42 | $685 | running to 2027-07-17 | -14.1% |
| 2026-07-17 | Leerink Partners | Outperform | maintained | $345.42 | $454 | replaced 2026-10-21, new $503 | -14.1% |
| 2026-07-17 | Baird | Outperform | maintained | $345.42 | $500 | replaced 2026-10-21, new $550 | -14.1% |
| 2026-07-17 | BTIG | Buy | maintained | $345.42 | $469 | replaced 2026-10-12, new $454 | -14.1% |
| 2026-07-16 | Truist Securities | Buy | maintained | $402.33 | $510 | running to 2027-07-16 | -3.5% |
| 2026-07-15 | Mizuho | Neutral | maintained | $388.97 | $500 | replaced 2026-07-17, new $400 | -6.6% |
| 2026-07-13 | TD Cowen | Buy | maintained | $407.12 | $520 | replaced 2026-07-17, new $485 | -1.0% |
| 2026-07-13 | RBC Capital | Outperform | maintained | $407.12 | $600 | replaced 2026-07-17, new $575 | -1.0% |
| 2026-07-09 | BMO Capital | Outperform | initiated | $411.55 | $518 | running to 2027-07-09 | -3.5% |
| 2026-07-06 | Evercore ISI Group | In-Line | maintained | $432.83 | $430 | within 5% of price when set | +2.5% |
| 2026-05-18 | Bank of America | Buy | maintained | $439.92 | $520 | running to 2027-05-18 | -6.2% |
| 2026-04-23 | Barclays | Overweight | maintained | $478.82 | $651 | replaced 2026-10-07, new $485 | +1.5% |
| 2026-04-22 | Leerink Partners | Outperform | maintained | $483.62 | $573 | replaced 2026-07-17, new $454 | +1.2% |
| 2026-04-22 | Baird | Outperform | maintained | $483.62 | $610 | replaced 2026-07-17, new $500 | +1.2% |
| 2026-04-22 | Piper Sandler | Overweight | maintained | $483.62 | $580 | replaced 2026-07-17, new $470 | +1.2% |
| 2026-04-22 | BTIG | Buy | reiterated | $483.62 | $574 | replaced 2026-07-17, new $469 | +1.2% |
| 2026-04-15 | Truist Securities | Buy | maintained | $468.36 | $580 | replaced 2026-07-16, new $510 | -3.1% |
| 2026-04-13 | Mizuho | Neutral | maintained | $458.96 | $525 | replaced 2026-07-15, new $500 | -2.8% |
| 2026-04-10 | BTIG | Buy | reiterated | $450.62 | $616 | replaced 2026-04-22, new $574 | -8.6% |
| 2026-04-09 | Goldman Sachs | Buy | maintained | $454.94 | $609 | running to 2027-04-09 | -6.4% |
| 2026-04-06 | Evercore ISI Group | In-Line | maintained | $452.58 | $480 | reached 2026-04-22 | -7.7% |
| 2026-03-17 | UBS | Neutral | maintained | $482.76 | $550 | running to 2027-03-17 | -0.6% |
| 2026-03-11 | Citigroup | Neutral → Buy | upgrade | $492.87 | $590 | replaced 2026-07-17, new $500 | +0.0% |
| 2026-02-24 | UBS | Neutral | maintained | $494.02 | $570 | replaced 2026-03-17, new $550 | -5.7% |
| 2026-01-27 | Freedom Capital Markets | Hold → Buy | upgrade | $525.04 | $610 | running to 2027-01-27 | -9.1% |
| 2026-01-27 | TD Cowen | Buy | initiated | $525.04 | $660 | replaced 2026-07-13, new $520 | -9.1% |
| 2026-01-26 | Barclays | Overweight | maintained | $528.81 | $712 | replaced 2026-04-23, new $651 | -8.5% |
| 2026-01-26 | Freedom Broker | Hold → Buy | upgrade | $528.81 | $610 | running to 2027-01-26 | -8.5% |
| 2026-01-23 | Citigroup | Neutral | maintained | $523.99 | $590 | replaced 2026-07-17, new $500 | -9.2% |
| 2026-01-23 | Evercore ISI Group | In-Line | maintained | $523.99 | $550 | within 5% of price when set | -9.2% |
| 2026-01-23 | Piper Sandler | Overweight | maintained | $523.99 | $620 | replaced 2026-04-22, new $580 | -9.2% |
| 2026-01-23 | Bernstein | Outperform | maintained | $523.99 | $750 | replaced 2026-07-17, new $685 | -9.2% |
| 2026-01-23 | BTIG | Buy | reiterated | $523.99 | $616 | replaced 2026-04-22, new $574 | -9.2% |
| 2026-01-09 | Bernstein | Outperform | maintained | $586.24 | $740 | replaced 2026-01-23, new $750 | +5.5% |
| 2026-01-07 | Barclays | Overweight | maintained | $592.27 | $686 | replaced 2026-01-26, new $712 | +4.5% |
| 2026-01-07 | BTIG | Buy | maintained | $592.27 | $616 | within 5% of price when set | +4.5% |
| 2025-12-18 | Truist Securities | Buy | maintained | $561.89 | $650 | replaced 2026-04-15, new $580 | +2.8% |
| 2025-12-17 | RBC Capital | Outperform | maintained | $556.86 | $650 | replaced 2026-07-13, new $600 | +1.9% |
| 2025-12-11 | Citigroup | Buy → Neutral | downgrade | $547.36 | $635 | replaced 2026-01-23, new $590 | -4.3% |
Also in Medical Devices
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.